Fluticasone Propionate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00588 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 35 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | 2-hydroxyethyl methacrylate sensitization | KG + DL |
| 2 | vulvar inverted follicular keratosis | KG + DL |
| 3 | alopecia mucinosa | KG + DL |
| 4 | telogen effluvium | KG + DL |
| 5 | alopecia areata | KG + DL |
| 6 | Quinquaud’s folliculitis decalvans | KG + DL |
| 7 | atopic dermatitis | KG + DL |
| 8 | polyp of vocal cord | KG + DL |
| 9 | hereditary hypotrichosis with recurrent skin vesicles | KG + DL |
| 10 | polyp of middle ear | KG + DL |
| 11 | epulis | KG + DL |
| 12 | fibroepithelial polyp | KG + DL |
| 13 | neoplastic polyp | KG + DL |
| 14 | polyp of frontal sinus | KG + DL |
| 15 | polyp of external auditory canal | KG + DL |
| 16 | polyp of vulva | KG + DL |
| 17 | uterine polyp | KG + DL |
| 18 | polyp of ureter | KG + DL |
| 19 | alopecia antibody deficiency | KG + DL |
| 20 | ichthyosis hystrix gravior | KG + DL |
| 21 | alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | KG + DL |
| 22 | Stankiewicz-Isidor syndrome | KG + DL |
| 23 | ichthyosis vulgaris | KG + DL |
| 24 | alopecia universalis onychodystrophy vitiligo | KG + DL |
| 25 | phototoxic dermatitis | KG + DL |
| 26 | white sponge nevus | KG + DL |
| 27 | annular atrophic lichen planus | KG + DL |
| 28 | lichen planus pigmentosus | KG + DL |
| 29 | hypertrophic lichen planus | KG + DL |
| 30 | dermatitis | KG + DL |
| 31 | asthma | KG + DL |
| 32 | lichen planus pemphigoides | KG + DL |
| 33 | acrodermatitis chronica atrophicans | KG + DL |
| 34 | acne keloid | KG + DL |
| 35 | persistent polyclonal B-cell lymphocytosis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.